Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aspire Biopharma Holdings, Inc. (ASBP : NSDQ)

• Company Description    Aspire Biopharma Inc. is a privately held, early-stage biopharmaceutical technology company. It engaged in the business of developing and marketing a disruptive technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals and supplements. Aspire Biopharma Inc., formerly known as PowerUp Acquisition Corp., is based in NEW YORK. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.35 Daily Weekly Monthly 20 Day Moving Average: 7,491,370 shares Shares Outstanding: 49.53 (millions) Market Capitalization: $17.15 (millions) Beta: 0.74 52 Week High: $9.86 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.87% -12.28% 12 Week -39.03% -48.72% Year To Date -96.99% -97.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 194 Candelaro Drive #233 - Humacao,PR 00791 USA ph: 908-987-3002 fax: - kevin@tradigitalir.com http://www.aspirebiolabs.com

• General Corporate Information    Officers Kraig T. Higginson - Chief Executive Officer and Chairman Ernest J. Scheidemann - Chief Financial Officer Michael C. Howe - Director Gary E. Stein - Director Barbara J. Sher - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 738920107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 49.53 Most Recent Split Date: (:1) Beta: 0.74 Market Capitalization: $17.15 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -508.70 12/31/24 - -123.98 Current Ratio 06/30/25 - - 03/31/25 - 0.22 12/31/24 - 0.00 Quick Ratio 06/30/25 - - 03/31/25 - 0.22 12/31/24 - 0.00 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -0.14 12/31/24 - -2.17 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©